Genitourinary Syndrome of Menopause: The Evidence on Vaginal Health

“No one warned me that sex would hurt, or that dryness would make ordinary days miserable. My doctor never even asked.”

Key finding: Genitourinary syndrome of menopause affects roughly half or more of postmenopausal women, yet most never discuss it with a clinician. Low-dose vaginal estrogen is the best-evidenced treatment, it works within weeks, and pooled data show no increased cancer-recurrence risk when breast cancer survivors use it. Moisturizers and lubricants help milder cases. Energy-based devices marketed for GSM show only short-term, mostly uncontrolled benefit, so the durable long-term evidence is still thin.

Dryness, burning, painful intercourse, recurrent urinary symptoms. These are not separate problems to tolerate; they are one syndrome caused by estrogen loss in the genital and urinary tracts. It has a name, it is common, and it is strikingly under-treated even though the treatments are cheap, well studied, and effective.

What GSM Is

Genitourinary syndrome of menopause, or GSM, is the 2014 consensus term that replaced the narrower “vulvovaginal atrophy.” It covers the vaginal, vulvar, and lower urinary-tract changes caused by falling estrogen after menopause: thinning and drying of vaginal tissue, loss of elasticity, painful sex, burning, itching, and urinary symptoms including recurrent infection and urgency.

It is not a niche complaint. Roughly half or more of postmenopausal women meet criteria for it, and many develop symptoms within a few years of their final period. A 2026 update in The Nurse Practitioner, reflecting the 2025 American Urological Association guideline developed with the Society of Urodynamics and the American Urogynecologic Society, calls GSM “highly prevalent” and notes that most women do not raise it with their providers.

The Treatment Gap

The gap between how common GSM is and how often it is treated is the central problem. Women do not bring it up; clinicians often do not ask. Dyspareunia, the pain with intercourse that GSM frequently causes, is common and concededly under-treated in gynecologic practice, per a 2026 review in the International Journal of Gynaecology and Obstetrics.

There is also a framing problem. Many women assume the only option is systemic hormone replacement, which they may not want or may have been told to avoid. That assumption is wrong: the first-line treatments for GSM are topical and local, not systemic.

The Data on Local Estrogen

Local (intravaginal) estrogen is the best-studied treatment for GSM. Low-dose vaginal estrogen creams, tablets, pessaries, and rings deliver a small amount of estradiol or estriol directly to vaginal tissue with minimal systemic absorption.

The Cochrane review, updated in 2016, pooled 30 randomized trials involving 6,235 women and found that intravaginal estrogen preparations improve the symptoms of vaginal atrophy compared with placebo, with no evidence of a difference in effectiveness between the various preparations (tablets, creams, rings). A 2024 meta-analysis of 18 randomized controlled trials (4,723 women) reached the same conclusion: intravaginal estrogen reliably improves signs and symptoms of vaginal atrophy.

The endometrial-safety question is the one most women worry about. The Cochrane review found no increase in adverse events overall, though higher-dose cream was associated with a greater increase in endometrial thickness than a ring, which the authors attributed to the higher doses used.

Non-Hormonal First-Line Options

For mild dryness, or for women who prefer to avoid hormones, vaginal moisturizers and lubricants are the reasonable starting point. The evidence base is thinner than for estrogen and the products are inconsistent.

A 2026 analysis in the Journal of the American Academy of Dermatology examined over-the-counter vaginal and vulvar moisturizers and found wide variation in ingredients, allergens, and marketing claims, with no standardized formulation. A 2026 randomized trial (VEMORA) in women on aromatase inhibitors compared vaginal estrogen with a non-hormonal moisturizer directly, giving a head-to-head look at non-hormonal options in a population where hormones are often restricted.

The honest summary: moisturizers and lubricants help symptoms for many women, cost little, and carry essentially no risk. They are a legitimate first step. For moderate to severe GSM, the evidence favors local estrogen.

Hormonal Alternatives: DHEA and Ospemifene

Two prescription options sit between lubricants and systemic HRT.

Vaginal dehydroepiandrosterone (prasterone or DHEA) is a local hormonal treatment that works without significant systemic estrogen exposure. A 2026 randomized trial of 172 postmenopausal women with moderate or severe dyspareunia compared vaginal DHEA with vaginal estradiol over 12 weeks. Both improved dyspareunia, DHEA in 92% and estradiol in 82%, and DHEA was significantly better for the women with the most severe pain. Estradiol was better at improving objective signs of atrophy.

Ospemifene is an oral selective estrogen receptor modulator. A 2023 systematic review in the journal Menopause found it effective for vulvovaginal atrophy compared with current treatments, with an acceptable tolerability and endometrial-safety profile. It is an option for women who want a pill rather than a vaginal product.

The Energy-Device Evidence Gap

Laser and radiofrequency devices are heavily marketed to menopausal women with promises of “vaginal rejuvenation.” The evidence does not match the marketing.

A 2026 observational cohort of 72 women found micro-ablative fractional carbon dioxide laser therapy produced short-term symptom improvement, with painful intercourse scores falling from 5.67 to 2.33 on a 10-point scale. But it was not sham-controlled, follow-up was short, and the authors themselves concluded that larger randomized sham-controlled trials with longer follow-up are needed before claiming comparative or durable benefit. A 2026 systematic review and meta-analysis of radiofrequency for GSM reached a similar position: promising signals, no high-quality long-term data. A 2024 meta-analysis of vaginal laser and topical therapies in breast cancer patients likewise found limited, low-certainty evidence.

The practical conclusion: these are expensive, often out-of-pocket, and the durability of their effect is unproven. They should not be treated as a replacement for evidence-based treatments.

Breast Cancer Survivors

Menopause symptoms and the fear of hormones collide most sharply for breast cancer survivors, the majority of whom are on endocrine therapy such as aromatase inhibitors that worsens GSM. This is the group where the “what about estrogen?” question is most fraught.

The data are reassuring. A 2025 systematic review and meta-analysis in the American Journal of Obstetrics and Gynecology examined vaginal estrogen use in breast cancer survivors and found no increased risk of recurrence or mortality. A 2023 systematic review reached the same conclusion on safety and on serum estradiol levels, finding that low-dose local treatments keep systemic absorption minimal. The VEMORA trial tested this population directly.

The nuance: local vaginal estrogen is not a decision any survivor should make alone. Guidelines differ on absolute and relative contraindications, and the choice belongs in a discussion with the oncology team. But the fear that any local estrogen means recurrence is not supported by the pooled evidence.

What to Do

Bottom line: If sex hurts, if dryness is a daily nuisance, or if urinary symptoms started around your final menstrual period, this is GSM and it is treatable. Start a moisturizer or lubricant for mild symptoms. For moderate to severe symptoms, low-dose vaginal estrogen is the evidence-backed first choice. Breast cancer survivors should discuss local options with their oncology team, but a large body of pooled data does not show increased recurrence.

Treatment options at a glance

Option	Evidence	Notes
Moisturizers / lubricants	Helps symptoms; variable product quality	First-line for mild dryness; no systemic hormone exposure
Low-dose vaginal estrogen (cream, tablet, pessary, ring)	Strongest evidence; works in weeks	Preferred for moderate to severe GSM; minimal systemic absorption
Vaginal DHEA (prasterone)	RCT; strong for severe dyspareunia	Local hormonal option without significant systemic estrogen
Ospemifene (oral)	Systematic review supports efficacy	Pill option; endometrial monitoring in some cases
Laser / radiofrequency	Short-term, mostly uncontrolled	Durability and comparative benefit unproven; often out-of-pocket

Research notes:

- Cochrane review (2016): 30 RCTs, 6,235 women. Intravaginal estrogen improves vaginal-atrophy symptoms vs placebo; no effectiveness difference across preparations. (Lethaby 2016)
- Intravaginal estrogen meta-analysis (2024): 18 RCTs, 4,723 women. Confirms improvement in atrophy signs/symptoms. (J Menopausal Med 2024)
- DHEA vs estradiol RCT (2026): 172 women. Dyspareunia improved in 92% (DHEA) vs 82% (estradiol); DHEA better for severe pain. (Maturitas 2026)
- CO2 laser cohort (2026): 72 women, dyspareunia 5.67 to 2.33, but no sham control or long-term follow-up. (Maturitas 2026)
- Radiofrequency meta-analysis (2026): promising signals, no high-quality long-term data. (Int Urogynecol J 2026)
- Vaginal estrogen and breast cancer (2025): meta-analysis found no increased recurrence or mortality risk. (Am J Obstet Gynecol 2025)
- Safety and serum estradiol in breast cancer (2023): low-dose local treatments keep systemic absorption minimal. (Clin Breast Cancer 2023)
- VEMORA (2026): head-to-head vaginal estrogen vs moisturizer in aromatase-inhibitor patients. (Breast Cancer Res Treat 2026)
- Ospemifene systematic review (2023): effective for vulvovaginal atrophy vs current therapies. (Menopause 2023)
- Dyspareunia review (2026): GSM under-treated; phenotype-based management. (Int J Gynaecol Obstet 2026)
- IMS recommendations (2025): 342 recommendations incl. GSM section. (Climacteric 2025)
- AUA 2025 guideline update (2026): GSM highly prevalent, under-discussed. (Nurse Pract 2026)
- OTC moisturizer analysis (2026): wide variation in ingredients/allergens/claims. (J Am Acad Dermatol 2026)

Sources

Lethaby, A., et al. (2016). Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD001500.pub3

Efficacy and Safety of Intravaginal Estrogen in the Treatment of Atrophic Vaginitis: A Systematic Review and Meta-Analysis. (2024). Journal of Menopausal Medicine. https://doi.org/10.6118/jmm.23037

Effects of vaginal dehydroepiandrosterone and estradiol on dyspareunia, a symptom of vulvovaginal atrophy in postmenopausal women. (2026). Maturitas. https://doi.org/10.1016/j.maturitas.2026.108924

Fractional CO2 laser monotherapy versus combination therapy with vaginal oestrogen for genitourinary syndrome of menopause. (2026). Maturitas. https://doi.org/10.1016/j.maturitas.2026.108966

Efficacy and Safety of Radiofrequency as a Treatment Modality for Genitourinary Syndrome of Menopause: A Systematic Review and Meta-Analysis. (2026). International Urogynecology Journal. https://doi.org/10.1007/s00192-026-06818-x

Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks. (2025). American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2024.10.054

Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors. (2023). Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2023.08.003

VEMORA: Vaginal Estrogen versus non-hormonal Moisturizer in women Receiving Aromatase inhibitors: a randomized, controlled trial. (2026). Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08025-0

Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy. (2023). Menopause. https://doi.org/10.1097/GME.0000000000002211

Assessment and management of dyspareunia in peri- and postmenopausal women: A phenotype-based gynecologic approach. (2026). International Journal of Gynaecology and Obstetrics. https://doi.org/10.1002/ijgo.71238

International Menopause Society (IMS) recommendations and key messages on women's midlife health and menopause. (2025). Climacteric. https://doi.org/10.1080/13697137.2025.2585487

Updates in care for patients with genitourinary syndrome of menopause. (2026). The Nurse Practitioner. https://doi.org/10.1097/01.NPR.0000000000000452

Allergens, moisturizing components, and marketing claims of over-the-counter vaginal and vulvar moisturizers: A product analysis. (2026). Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.06.022